BRIEF published on 09/15/2026 at 15:40, 1 month 27 days ago Revive Therapeutics Aims to Expand Bucillamine Portfolio Intellectual Property Orphan Diseases Medical Countermeasures Government Partnerships Bucillamine
PRESS RELEASE published on 09/15/2026 at 15:35, 1 month 27 days ago Revive Therapeutics to Expand Bucillamine IP and Orphan Drug Portfolio Across Medical Countermeasures and Rare Diseases Revive Therapeutics Ltd. outlines strategy to build protected bucillamine franchise for medical countermeasures, rare diseases, and government preparedness programs Rare Diseases Medical Countermeasures Revive Therapeutics Ltd. Bucillamine Franchise Government Preparedness
BRIEF published on 08/19/2026 at 20:40, 2 months 23 days ago Revive Therapeutics Proposes Shares for Debt Settlement Debt Settlement Canadian Securities Exchange Shares Issuance Revive Therapeutics Biodefense Research
PRESS RELEASE published on 08/19/2026 at 20:35, 2 months 23 days ago Revive Therapeutics Announces Proposed Shares for Debt Settlement Revive Therapeutics Ltd. announces proposed debt settlement by issuing Settlement Shares to settle outstanding trade payables. Subject to CSE approval Debt Settlement Settlement Shares CSE Approval Revive Therapeutics Ltd. Biodefence
BRIEF published on 08/19/2026 at 14:45, 2 months 24 days ago Revive Therapeutics Advances Biodefence Strategy with Bucillamine Medical Countermeasures Pandemic Preparedness Government Partnerships Bucillamine Biodefence
PRESS RELEASE published on 08/19/2026 at 14:40, 2 months 24 days ago Revive Therapeutics Outlines Strategy to Build a Biodefence and Pandemic Preparedness Therapeutics Portfolio Revive plans to expand bucillamine use in biodefence with positive DRDC findings, government opportunities, and complementary therapies, focusing on medical countermeasures Bucillamine Biodefence Revive DRDC Government Opportunities
BRIEF published on 08/15/2026 at 00:55, 2 months 28 days ago Revive Therapeutics Grants 15.5 Million Stock Options Stock Options Life Sciences Biodefense Pandemic Preparedness Revive Therapeutics
PRESS RELEASE published on 08/15/2026 at 00:50, 2 months 28 days ago Revive Therapeutics Reports Grant of Options Revive Therapeutics Ltd. authorized the grant of 15,500,000 incentive stock options to key team members. The options aim to drive performance and incentivize excellence in advancing corporate objectives Stock Options Incentive Pandemic Preparedness Revive Therapeutics Ltd. Biodefence
BRIEF published on 08/12/2026 at 14:00, 3 months ago Revive Therapeutics Announce Positive Study Results on Bucillamine for Nerve-Agent Exposure Bucillamine Revive Therapeutics Nerve-agent Research DRDC Study Biodefence
PRESS RELEASE published on 08/12/2026 at 13:55, 3 months ago Revive Therapeutics Reports Positive Results from DRDC Bucillamine Nerve-Agent Research Study Revive Therapeutics announces positive results from DRDC research study on bucillamine in nerve-agent exposure model, showing preservation of GABA receptors. Further studies planned Bucillamine Revive Therapeutics DRDC Research Study Nerve-agent Exposure GABA Receptors
Published on 11/12/2026 at 15:55, 2 hours 1 minute ago DIAGENS Leads in Two Major Global AI Benchmarks and Extends Chest and Abdominal CT Analysis to 509 Imaging Targets, Ushering in a New Era for Medical Imaging AI
Published on 11/12/2026 at 14:31, 3 hours 25 minutes ago First Breach Inc. Announces Third Quarter 2026 Earnings Conference Call
Published on 11/12/2026 at 14:00, 3 hours 56 minutes ago GameSquare Announces Peaky Blinders Digital Fan Experience, Advancing the Company's IP Monetization Strategy
Published on 11/12/2026 at 14:00, 3 hours 56 minutes ago NuRAN Wireless Highlights Recurring Revenue Economics and Growth Potential of Its 5,092-Tower Contracted NaaS Portfolio
Published on 11/12/2026 at 13:45, 4 hours 11 minutes ago Amarc and Freeport Successfully Complete 2026 Joy Copper-Gold District Exploration Program
Published on 11/12/2026 at 17:45, 11 minutes ago Intershop disposes its fully developed Lehenmatt properties in Basel
Published on 11/12/2026 at 17:45, 11 minutes ago CTS EVENTIM generates further profitable growth in the first nine months of 2026
Published on 11/12/2026 at 17:40, 16 minutes ago LIGHTON: Information concerning the total number of voting rights and shares in the share capital as of 30 september 2026.
Published on 11/12/2026 at 16:40, 1 hour 16 minutes ago Rockwell Automation Introduces LogixEdge Controllers for Software-Defined Automation
Published on 11/12/2026 at 17:40, 16 minutes ago Financial information for the period ended 30 September 2026
Published on 11/12/2026 at 08:56, 8 hours 59 minutes ago Number of shares and voting rights - October 2026 (In French only)
Published on 11/12/2026 at 08:40, 9 hours 16 minutes ago FREY forms a €400 million equity partnership with GIC to invest in premium European retail parks
Published on 11/10/2026 at 17:31, 2 days ago CNP Assurances SA announces the success of the issuance of a €500 million Tier 2 subordinated bond.
Published on 11/10/2026 at 14:00, 2 days 3 hours ago Guillemot Corporation S.A. | Weekly report share buyback from November 2 to November 6, 2026